hodgkin's%20lymphoma
HODGKIN'S LYMPHOMA

Hodgkin's lymphoma is a malignancy that arises from germinal center B cell.

Histologically, there is a presence of multinucleated giant cells in a mixed inflammatory background.

It is also known as Hodgkin's disease, Hodgkin lymphoma or Hodgkin disease.

It commonly affects individuals ages 15-30 years old and those 55 years old and above.

The key morphologic characteristics include presence of Reed-Sternberg cells and lymphocyte-predominant cells.

Hodgkin's Lymphoma References

  1. American Cancer Society. Hodgkin lymphoma. American Cancer Society website. http://www.cancer.org/acs/groups/cid/documents/webcontent/003105-pdf.pdf. 2014.
  2. Bartlett NL, Foyil KV. Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier; 2014:2018-2032.e4.
  3. Das P, Ng A, Constine LS, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-favorable prognosis stage I and II. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/HodgkinsLymphomaFavorablePrognosisStageIAndII.pdf. 2011.
  4. Eichenauer DA, Engert A, André M, et al; ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(Suppl 3):iii70-iii75. https://annonc.oxfordjournals.org/content/25/suppl_3/iii70.full.pdf. PMID: 25185243
  5. Eichenauer DA, Engert A, Diehl V. Hodgkin lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weltz JI, Anastasi J. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA; 2013:1138-1156.
  6. Follows GA, Ardeshna KM, Barrington SF, et al; British Committee for Standards in Haematology. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):34-49. http://onlinelibrary.wiley.com/doi/10.1111/bjh.12878/epdf. PMID: 24712411
  7. German Hodgkin Study Group. Hodgkin lymphoma. GHSG website. https://en.ghsg.org/disease-stages. 2016.
  8. Hernandez-Ilizaliturri FJ. Hodgkin lymphoma treatment protocols. Medscape website. http://emedicine.medscape.com/article/2006680-overview. Aug 2014.
  9. Horwitz S, Yahalom J. Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma. UptoDate website. http://www.uptodate.com/contents/initial-treatment-of-advanced-stage-iii-iv-classical-hodgkin-lymphoma?source=related_link. Aug 2015.
  10. Jaffe ES, Pittaluga S, Anastasi J. Pathologic basis for the classification of non-hodgkin and hodgkin lymphomas. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weltz JI, Anastasi J. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA; 2013:1112-1129.e2.
  11. Mauch PM, Aster JC, LaCasce AS. Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma. UptoDate website. http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-nodular-lymphocyte-predominant-hodgkin-lymphoma?source=search_result&search=nodular+lymphocyte+predominant+hodgkin&selectedTitle=2~12. Nov 2014.
  12. National Cancer Institute. Adult hodgkin lymphoma treatment-for health professionals (PDQ®). National Cancer Institute website. http://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq#section/all. Jan 2016.
  13. National Cancer Institute. Childhood hodgkin lymphoma treatment-for health professionals (PDQ®). National Cancer Institute website. http://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq#section/all. Jan 2016.
  14. National Cancer Institute. Drugs approved for hodgkin lymphoma. National Cancer Institute website. http://www.cancer.gov/about-cancer/treatment/drugs/hodgkin-lymphoma. Sep 2014.
  15. National Comprehensive Cancer Network Hodgkin Lymphoma Panel. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): Hodgkin lymphoma. Version 2.2015. NCCN website. http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. 2015.
  16. Roberts KB, Younes A, Hodgson DC, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-unfavorable clinical stage I and II. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/HodgkinsLymphomaUnfavorableClinicalStageIAndII.pdf. 2015.
  17. Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Oct 26, 2015. Clin Transl Oncol. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689754/pdf/12094_2015_Article_1429.pdf. PMID: 26497354
  18. Sweetman SC, Blake PS, Brayfield A, et al, eds. Martindale: The complete drug reference. MedicinesComplete website. https://www.medicinescomplete.com/mc/martindale/current/. 2016.
  19. Terezakis SA, Metzger ML, Constine LS, et al. ACR Appropriateness Criteria® on pediatric Hodgkin’s lymphoma. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/PediatricHodgkinLymphoma.pdf. 2012.
  20. Wilder RB, Ng A, Constine LS, et al. ACR Appropriateness Criteria® on Hodgkin’s lymphoma-stage III and IV. American College of Radiology website. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/HodgkinsLymphomaStageIIIAndIV.pdf. 2010.
  21. Canellos GP. Overview of the treatment of classic Hodgkin lymphoma in adults. UpToDate. www.uptodate.com.. 15 Feb 2019.
  22. LaCasce AS. Treatment of relapsed or refractory classic Hodgkin lymphoma. UpToDate. www.uptodate.com. 12 Sep 2018.
  23. LaCasce AS, Ng AK. Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma. UpToDate. www.uptodate.com. 31 May 2019.
  24. National Comprehensive Cancer Network. Hodgkin's lymphoma. version 2.2019. NCCN. www.nccn.com. 15 Jul 2019.
  25. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Hodgkin lymphoma version 2.2020. NCCN. https://www.nccn.org. 17 Apr 2020. Accessed 13 May 2020.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.